Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Raperport, Claudia; Chronopoulou, Elpiniki; Homburg, Roy
• Is Part Of: Expert review of endocrinology & metabolism. Volume 16:Issue 2(2021)
• Page Start: 37
• Page End: 47
• Publication Date: 2021-03-04
• Subjects: Diabetes -- insulin resistance -- metformin -- obesity -- pregnancy -- polycystic ovarian syndrome -- subfertility; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1080/17446651.2021.1889366
• Languages: English
• ISSNs: 1744-6651

Abstract

ABSTRACT: Introduction: This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS). Areas covered: After searching Medline, Embase and CINAHL, all important large clinical trials and observational studies plus systematic reviews, meta-analyses and Cochrane reviews have been summarized here. The results have been compared to culminate in a thorough review and discussion on the use of metformin in relation to reproductive outcomes for women with PCOS. The role of metformin in PCOS is explored both in terms of achieving conception and during pregnancy. The existing evidence around metformin use is summarized both during the preconceptual period and during pregnancy, in relation to reproductive outcomes. Expert opinion: Metformin is a widely used medication, often prescribed to improve reproductive outcomes for women with PCOS. However, the evidence remains equivocal regarding its efficacy both in optimizing fertility and pregnancy outcomes. More research is required with special emphasis on metformin use within different populations, including ethnic groups and women with varying BMI ranges.